Long term follow-up of CEOP in the treatment of HIV related non- Hodgkin's lymphoma (NHL)

Australian and New Zealand Journal of Medicine

Volumn 28, Issue 1, 1998, Pages 28-32

  Davis, A J ^a   Goldstein, D ^a   Milliken, S ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

AIDS; Antineoplastic agents; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRATHECAL DRUG ADMINISTRATION; LONG TERM CARE; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 0031936829     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1998.tb04455.x     Document Type: Article

References (22)

1. Centers for Disease Control: Diffuse, undifferentiated non-Hodgkin's Lymphoma among homosexual males - United States. MMWR 1982; 31: 277-9.
2. Centers for Disease Control: Revision of the case definition of acquired immunodeficiency syndrome for national reporting United States. MMWR 1985; 34: 373-5.
3. National AIDS Registry. Australian HIV Surveillance Report 1995; 11: 22.
4. Tirelli U, Errante D, Carbone A, Gloghini A, Vaccher E. Malignant lymphomas in patients with HIV infection. Leukaemia Lymphoma 1996; 22: 245-57.
5. Kaplan L, Abrams D, Feigal E et al. AIDS-Associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261: 719-924.
6. Irwin D, Kaplan L. Clinical aspects of HIV-related lymphoma. Curr Opin Oncol 1993; 5: 852-60.
7. Roithmann S, Toledano M, Tourani J et al. HIV-associated non-Hodgkin's Lymphomas: Clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumours. Ann Oncol 1991; 2: 289-95.
8. Levine A, Wernz J, Kaplan L et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. JAMA 1991; 266: 84-8.
9. Kaplan L, Straus D, Teata M et al. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Fngl J Med 1997; 336: 1641-8.
10. Hryniuk W. The importance of dose intensity in outcome of chemotherapy. In: DeVita VTJ, Hellman SM, Rosenberg SA (Eds). Important advances in oncology. Philadelphia: Lippincott, 1988: 283-6.
11. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive NHL: The International non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987.
12. Al-Ismail SA, Whittaker JA, Gough J. Combined chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 1987; 23: 1374-84.
13. De Lena M, Maiello E, Lorusso V et al. Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas - a randomised trial. Oncol Tumour Pharmacother 1989; 6: 163-9.
14. Deliliers L, Butti C, Baldini L et al. A co-operative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma. Haematologica 1995; 80: 318-24.
15. Fisher R, Gaynor E, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 29: 1002-6.
16. Freter CE. Acquired Immunodeficiency Syndrome-Associated Lymphomas. J Nat Cancer Inst Monogr 1990; 10: 45-54.
17. Boyle M, Swanson C, Turner J et al. Definition of two distinct types of AIDS-associated non-Hodgkin's lymphoma. Br J Haematol 1990; 76: 506-12.
18. Mocharnuk RS, Ghadialy A, Tulpule A, Espina B, Levine A. Long-term disease free survival in AIDS-related lymphoma. Proc ASCO 1996; 15: Abstr 855.
19. Vaccher E, Umberto T, Spina M et al. Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: A single-institute study of 96 patients. J Clin Oncol 1996; 14: 2217-23.
20. Newell M, Goldstein D, Milliken S et al. Phase I/II trial of filgrastim (r-met HuGCSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma. Ann Oncol 1996; 7: 1029-36.
21. Sparano J, Wiernik P, Hu X et al. Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with Human Immunodeficiency Virus-associated non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 11: 3026-35.
22. Sparano J, Wiernik P, Strack M, Leaf A, Becker N, Valentine E. Infusional cyclophosphamide, doxorubicin and etoposide in Human Immunodeficiency Virus and Human T-cell Leukaemia Virus Type-1 related non-Hodgkin's lymphoma. A highly active regimen. Blood 1993; 81: 10: 2810-5.